PETMED EXPRESS INC (PETS): Nasdaq/NYSE listing notice — PetMed Express warns Q2 net sales down ~25% YoY; receives Nasdaq delisting notice

PETMED EXPRESS INC

2026-Q2 EPS reported -$2.05 revenue$95,544,000

Preliminary Q2 net sales estimated at $43.4M-$44.5M vs $58.0M (restated) prior year.
Six-month net sales estimated at $94.5M-$95.6M vs $124.3M (restated) prior year.
Cannot estimate operating income due to pending goodwill impairment analysis.
Cash $36.1M, no debt as of September 30, 2025.
Nasdaq non-compliance for late Q1 and Q2 10-Qs; compliance plan update due by Nov 28, 2025.

item 2.02 item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PETMED EXPRESS INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

November 12, 2025, the Company received an expected notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), which indicated that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 (the “Q2 10-Q”), in addition to its continued delinquency in filing its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 (the “Q1 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires Nasdaq-listed companies to timely file all required periodic

View on SEC.gov

16 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

PETMED EXPRESS INC filing history →

Source: SEC EDGAR

accession 0001040130-25-000086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.